Financings Routine +

Mountain Valley MD Announces Strategic Non-Brokered Private Placement of Units and Concurrent Shares for Debt Transaction

MVMD Secures $2M Lifeline at Steep Discount as Warrant Strike Aligns with Recent Price Spike

By The Northwire Desk — AI Analysis Mar 31, 2026 · 08:30 MVMD · 0.08 Mountain Valley MD Holdings Inc.

Executive Summary

On 2026-03-31, Mountain Valley MD announced a non-brokered private placement of up to 80 million units at CAD 0.025 per unit, targeting gross proceeds of up to CAD 2 million.
Each unit consists of one common share and one warrant. Warrants are exercisable at CAD 0.08 per share for 12 months, with an acceleration clause triggering if the CSE VWAP reaches or exceeds CAD 0.12 for ten consecutive trading days.
Concurrently, the company will settle approximately CAD 485,000 in outstanding debt through two shares-for-debt transactions: CAD 385,000 settled at CAD 0.017 per share, and CAD 100,000 settled at CAD 0.06 per share.
Net proceeds are allocated to general working capital. The offering is expected to close in April 2026, pending CSE and regulatory approvals.
All issued shares and units are subject to a statutory four-month and one-day hold period.

Material Impact

The financing is a standard survival raise for a cash-burning micro-cap. While it extends the operational runway, the terms are highly dilutive relative to the recent price action.
The unit price of CAD 0.025 represents a 68.75% discount to the recent market price of CAD 0.08. This discount signals that the company required a steep incentive to attract capital, reflecting underlying liquidity and execution risk.
The concurrent debt settlement at CAD 0.017 and CAD 0.06 further increases the share count. The CAD 0.017 conversion price is significantly below the financing price, indicating distressed debt restructuring.
The warrant strike price of CAD 0.08 exactly matches the current trading price. This creates a structural ceiling on near-term upside, as warrant holders will likely sell into any rally approaching the strike to realize gains, while the acceleration clause at CAD 0.12 incentivizes management to maintain price momentum only if it benefits warrant exercise.
In the context of the December 2025 updates highlighting strong Agrarius trial data and Quicksome commercialization, this financing confirms that trial success has not yet translated into self-sustaining cash flow. The raise is necessary but does not alter the fundamental commercialization timeline.

MVMD · Price

Company Overview

Mountain Valley MD operates across three core technology platforms: Quicksome (nutraceutical delivery), Agrarius (agricultural plant signaling), and Soluvec (animal health formulations).
Flagship project: Agrarius, a plant-signaling additive applied via sprayer. Recent trials in Brazil and Colombia demonstrated yield increases ranging from 6% to over 50% across citrus, corn, sugarcane, soybeans, cotton, and potatoes, alongside improved drought resilience and reduced HLB (citrus greening) symptoms.
Quicksome focuses on sublingual nutraceutical delivery through an exclusive U.S. GMP manufacturing partnership, currently supporting Circadian Wellness products.
Soluvec 1% is a stabilized ivermectin formulation for livestock and aquaculture, currently licensed in Bangladesh with ongoing strategic reviews for Latin American expansion.

More from Mountain Valley MD Holdings Inc.